Web Research

What the Web Says About Greggs

The web reveals a stock deep in a sentiment drawdown that the historical filings don't fully capture: Greggs was the worst-performing stock on the FTSE 250 in 2025, down roughly 43%, and hit its lowest share price since the pandemic in July 2025 on a first-half profit miss. Yet the tape is split — J.P. Morgan initiated coverage in December 2025 with an Overweight rating and a 2,110p Dec-2027 target (implying ~35% upside), while Jefferies downgraded to Hold and slashed its target from 2,500p to 1,610p in February, and Berenberg cut its target from 2,170p to 2,090p in March 2026. The single most important off-filing signal: Greggs has peaked capex (£287.5m in 2025), guided that it will fall to ~£200m in 2026 and £150–170m from 2027, which management explicitly says will unlock capacity for additional returns to shareholders — the setup for a classic re-rating if like-for-like sales stabilise.

What Matters Most

**#1 — Worst FTSE 250 performer of 2025, down ~43%.** Shares fell from a May 2025 high of 2,237.88p to a November 2025 low of 1,407.20p. The proximate causes per press coverage: a hot UK summer, slowing like-for-like sales, a 14% H1 profit decline, and a Jefferies-flagged risk that GLP-1 weight-loss drugs could structurally dent demand from Greggs' highest-frequency customers. Source: Yahoo Finance / Motley Fool UK (22-Aug-2025, 10-Nov-2025), Bloomberg (29-Jul-2025), Reuters.

**#2 — Capex peaked in 2025; shareholder returns set to expand from 2027.** Preliminary results (3-Mar-2026) confirm 2025 capex of **£287.5m**, falling to **~£200m in 2026** and a **£150–170m range from 2027**, at which point management explicitly stated "cash generation would create capacity for additional returns to shareholders." The total ordinary dividend was held at **69.0p** (final 50.0p recommended), yielding ~4.2%. Source: Proactive Investors, 3-Mar-2026.

**#3 — J.P. Morgan bull call: 2,110p target, ~35% upside.** In early December 2025 (at 1,590p) JPM initiated coverage with an Overweight rating, citing a valuation at "trough levels despite sector-leading operating metrics and clear catalysts for recovery." Shares jumped ~5-6% on the call. The brokerage sees Greggs positioned for structural growth. Source: share-talk.com, Investing.com, Proactive Investors.

**#4 — Analyst sentiment is bifurcated and targets have been slashed.** Jefferies downgraded to Hold on 9-Feb-2026, cutting its target from **2,500p to 1,610p** — a 36% reduction — and on 14-Apr-2026 reiterated Hold. Berenberg trimmed from **3,040p → 2,170p → 2,090p** over successive updates (the latter on 16-Mar-2026, though still rated Buy). MarketBeat shows consensus Hold with average target of **1,993p**; eToro shows **2,050p** average; TipRanks (6 analysts) has ranges from **1,330p to 2,200p** with a median ~1,651–1,731p. Sources: TipRanks, Sharecast, Daily Political, Marketbeat.

**#5 — Weight-loss drugs (GLP-1) flagged as structural demand risk.** Jefferies explicitly cited GLP-1 weight-loss drugs (Ozempic, Mounjaro) as a risk that could "curb sales and profit growth by reducing demand from the bakery chain's most frequent customers," contributing to a 6% single-day share drop when the report landed. This is a thesis-changing risk not visible in prior filings. Source: Reuters / Seeking Alpha / Motley Fool UK.

#6 — FY2025 trading: 6.9% sales growth but 9.4% profit decline. Total sales reached £2.15bn (+6.8%), like-for-like sales in company-managed shops were +2.4%, franchise LFL was +4.3%, and the estate expanded to 2,739 shops (+121 net). However, underlying PBT fell 9.4% to £171.9m on cost inflation and strategic investment. Greggs guided 2026 profit "similar underlying level to 2025," dependent on a consumer recovery. Source: Proactive Investors, 3-Mar-2026.

#7 — Long-term whitespace reaffirmed: >3,000 UK shops. Management explicitly stated it sees "a clear long-term opportunity for significantly more than 3,000 UK shops," with 2026 guidance of ~120 net openings (though down from an earlier 145 plan). Evening trading (9.4% of mix, fastest-growing daypart) and delivery (+8.1% to 6.8% of sales) continue to scale. The Greggs Rewards app is now scanned in 26.7% of transactions (up from 20.1% in 2024). Source: Proactive Investors / AskTraders / TipRanks.

**#8 — Mixed insider signal: CFO sold, CEO & new Chair bought.** CFO Richard Hutton sold **65,000 shares at 2,851p (£1.85m)** on 8-Oct-2024 and another **7,438 at 1,571p (£117k)** on 4-Nov-2025. Offsetting: CEO Roisin Currie made a token buy of 14 shares at 2,886p (Oct-2024); new non-executive Matthew Davies acquired **1,249 shares at 1,600p (£20k)** on 20-Aug-2025 (near the 52-week low). Insider ownership remains below 1% (~£1.7–3.0m total) — typical for a UK plc but not a "skin-in-the-game" story. Source: Daily Political, Modern Readers, Enterprise Leader.

#9 — Institutional ownership concentrated; notable hedge-fund rotation. Top holder Silchester International disclosed a 5.00% stake (27-Nov-2025). Schroders holds 4.69%, National Bank Financial 3.98%, MFS International 3.46% (net added 1.01m shares, +39.9%), Ninety One added 580k (+33%). Offsetting: Royal London, Fiduciary Management, and JPMorgan Securities (market-maker) fully exited; BlackRock cut by 54.9%. Institutions own ~88% of the float. Source: FT/FactSet, 31-Dec-2025.

#10 — Moorhead board situation and governance churn. Robert Moorhead (ex-WH Smith CFO) was announced as incoming non-executive director / audit committee chair, but Greggs' filings show a 19-Nov-2025 "Board Update" noting a withdrawal of a Non-Executive Director candidacy, followed by a 16-Dec-2025 appointment of a different NED. Sarah Dickson is Company Secretary / General Counsel. Matthew Davies is Independent Non-Executive Chairman. Source: FinancialReports.eu filings feed.

Recent News Timeline

No Results

Analyst Targets — The Divide

Share Price (p)

1,643

JPM Target (p)

2,110

Dividend Yield (%)

4.2

P/E (TTM)

13.8

Consensus rating is Hold (MarketBeat: 0 strong sell, 1 sell, 6 hold, 8 buy, 5 strong buy across 20 analysts). The ~500p range between JPM's bull case (2,110p) and Jefferies' base (1,610p) reflects genuine debate over whether 2025 weakness is cyclical (weather, inflation, consumer squeeze) or structural (UK saturation, GLP-1 demand destruction).

What the Specialists Asked

Insider Spotlight

No Results

Roisin Currie (CEO). Appointed May 2022. Internal promotion from Retail & Property Director — a shop-floor operator, not a finance CEO. Total comp £1.81m (36% salary / 64% variable). Personal ownership 0.033%. Her 14-share October 2024 purchase is symbolic alignment only. Simply Wall St has twice flagged pay-growth caution.

Richard Hutton (CFO). Long-tenured CFO. Two material sells within 13 months: £1.85m at 2,851p and £117k at 1,571p. The timing (both near or after highs on a price scale that subsequently declined 43%) reads as prudent diversification, not a conviction signal. No corresponding buys.

Matthew Davies (Independent Non-Executive Chair). £20k purchase at 1,600p on 20-Aug-2025 — a modest but real commitment at a price within 14% of the eventual 52-week low. Worth tracking for further adds.

Governance snapshot. Board churn: a 19-Nov-2025 "Board Update" noted a withdrawn NED candidacy; a 16-Dec-2025 announcement confirmed a different NED appointment. Robert Moorhead (ex-WH Smith CFO) is signalled as incoming audit-committee chair. Tamara Rogers joined as NED in 2025 with FTSE-100 marketing experience. Aggregate insider ownership remains under 1% of issued share capital (~£1.7–3.0m) — standard for UK plcs, not a "founder-aligned" story.

Industry Context

UK food-to-go is fragmented but Greggs leads. The UK bakery sector has over 4,000 independent operators; Greggs' 19.6% breakfast-market share makes it the single largest player, ahead of McDonald's in morning occasions. Breakfast contributes ~20-24% of group revenue by volume.

Competitive pressure is intensifying from two sides.

QSR chains broadening breakfast/snack menus — McDonald's and Pret a Manger are explicit competitive threats called out in SWOT coverage.
Structural demand risk from GLP-1 weight-loss drugs — Jefferies' downgrade thesis is that the most-frequent users of chains like Greggs are disproportionately exposed to the Ozempic/Mounjaro consumer shift. This is novel and unprovable from historical data, but has become an embedded part of the bear case.

Broader UK hospitality backdrop is weak. FT headlines across Q1-2026 paint a gloomy sector — "No end in sight for restaurant and pub pain" (19-Feb-2026), "UK restaurants offer deep discounts in 'last resort' to lure spend-shy diners" (1-Feb-2026), "Upmarket tastes leave UK high street coffee chains out in the cold" (17-Jan-2026). Greggs' over-index to value positioning is a defensive feature in this environment, but consumer-spend sensitivity is a headwind.

ESG / sustainability is a differentiator. Carbon intensity down 41.8% since 2019; net-zero target by 2040; on 13-Apr-2026 Greggs raised its 2030 sustainability ambitions after hitting key interim ESG milestones. Packaging recyclability, renewable energy use, and 45 Outlet shops (affordability format) have been expanded.